EUCTR2006-006309-96-ES进行中（未招募）不适用
Estudio descriptivo, aleatorizado, abierto, con grupos paralelos, de 3 meses de duración para explorar y comparar la percepción y la satisfacción en cuanto a dos mecanismos de administración de Etanercept diferentes (autoinyectable de Etanercept y jeringa precargada de Etanercept) en pacientes con psoriasis.A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjector and the Etanercept Prefilled Syringe) in Patients with Psoriasis.
Wyeth Pharmaceuticals France0 个研究点目标入组 524 人开始时间: 2007年7月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 524
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA
- •· Eligible for treatment with etanercept according to Summary of Product Characteristics (SmPC), and applicable local guidelines.
- •· Aged 18 years or more
- •· Willing and able to self-inject etanercept.
- •· Able to store test drug at 2-8°C.
- •· Negative serum ß-human chorionic gonadotropin (ß-HCG) pregnancy test at baseline (week 0) for all women of childbearing potential. Sexually active women of childbearing potential must use a medically acceptable form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception. Sexually active men must agree to use a reliable form of contraception during the study.
- •· Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol-specific procedures are performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· Prior experience of biologic treatment for their Psoriasis including etanercept.
- •· Sepsis or risk of sepsis.
- •· Current or recent infections, including chronic or localized.
- •· Latex sensitivity.
- •· Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study.Patients with the following conditions or risk factors should only be entered into the study if the investigator has conducted and documented a full risk/benefit evaluation:
- •· History of recurring or chronic infection, or underlying condition which may predispose patients to infections e.g. Tuberculosis (TB) infection (Note: follow local country guidelines for appropriate screening and treatment of tuberculosis in the setting of anti-TNF therapy), serious infection (infection associated with hospitalization and/or intravenous antibiotics) within 1 month of test article administration or active infection at screening, open cutaneous ulcers, known human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) positive.
- •· Current or prior history of blood dyscrasias. Abnormal safety baseline blood test e.g. hemoglobin =85 g/L; hematocrit =27 %; platelet count =125 x 109 /L; white blood cell count =3.5 x 109 /L; serum creatinine =175 µmol/L; aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) =2 times the laboratory’s upper limit of normal.
- •· Pre-existing or recent onset CNS demyelinating disease.
- •· Cardiovascular conditions, e.g., myocardial infarction within 12 months of the screening visit, unstable angina pectoris, class III or IV congestive heart failure as defined by the New York Heart Association classification (4) or decompensated congestive heart failure.
- •· Uncontrolled conditions, e.g., diabetes mellitus, hypertension (defined as screening systolic blood pressure > 160 mm Hg or screening diastolic blood pressure > 100 mm Hg), severe pulmonary disease requiring hospitalization or supplemental oxygen.
- •· At increased risk of malignancy.
研究者
相似试验
进行中（未招募）
不适用
Estudio prospectivo, abierto, no aleatorizado y multicéntrico para investigar la seguridad y la tolerabilidad del voriconazol como tratamiento primario de la aspergilosis invasiva y de infecciones por hongos filamentosos, entre ellos, especies de Scedosporium o Fusarium, en pacientes pediátricosA PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTSTratamiento de la aspergilosis invasiva y de la infección por hongos filamentosos raros, como las especies de Scedosporium o Fusarium.Treatment of proven or probable invasive aspergillosis (IA) and rare molds such asScedosporium or Fusarium species.MedDRA version: 9.1Level: LLTClassification code 10003488Term: AspergillosisMedDRA version: 9.1Level: LLTClassification code 10051919Term: Fusarium infectionMedDRA version: 9.1Level: LLTClassification code 10059045Term: Scedosporium infectionEUCTR2008-005275-10-ESPfizer, S.A.36
进行中（未招募）
不适用
Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en pacientes infectados por el virus de la inmunodeficiencia humana.” Open label, prospective, randomized, crossed study of the effect of Hidroxychloroquine, 200 mg QD, on inflammatory and metabolic factors related to cardiovascular disease in human immunodeficiency virus infected patientsInfección por el virus de la inmunodeficiencia adquiridaMedDRA version: 9.1Level: LLTClassification code 10020160Term: HIV diseaseEUCTR2007-007018-12-ESCarlos Alonso-Villaverde Lozano, Hospital Universitari Sant Joan de Reus
进行中（未招募）
1 期
Estudio abierto, aleatorizado, controlado y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de MIRCERA por vía subcutánea frente a la ausencia de tratamiento con ESA, en el tratamiento de la anemia en pacientes con nefropatía crónica después del trasplante renal. A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.EUCTR2007-003955-35-ESF. Hoffmann-La Roche Ltd318
进行中（未招募）
不适用
Estudio abierto, aleatorizado y comparativo, para establecer la seguridad y eficacia de Bondronat i.v. (6 mg) en pacientes con cáncer de mama y metástasis óseas, que presentan dolor de moderado a grave”.Dolor en metástasis óseas de cáncer de mama.Classification code 10049038EUCTR2005-004760-23-ESRoche Farma, S.A.
进行中（未招募）
不适用
Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónicaEnfermedad renal terminal (ESRD)EUCTR2005-004052-12-ESAsociación Científica para la investigación Nefrológica (ACINEF)